WVE 006
Alternative Names: AIMers; GSK-5462688; SERPINA1 stereopure nucleic acid therapeutic - WaVe Life Sciences; WVE-006Latest Information Update: 31 Aug 2026
At a glance
- Originator WaVe life Sciences
- Class Amides; Amino sugars; Drug conjugates; Oligonucleotides
- Mechanism of Action SERPINA1 protein expression modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Alpha 1-antitrypsin deficiency
Most Recent Events
- 30 Jul 2026 Wave Life Sciences plans to meet with the US FDA to discuss a potential accelerated approval pathway for WVE 006 by mid of 2026
- 18 May 2026 Efficacy and adverse evenst data from a phase I RestorAATion-1 trial for Alpha 1-antitrypsin deficiency released by WaVe life Sciences
- 02 Feb 2026 WVE 006 is no longer licensed to GSK in Workd